Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection?
- PMID: 23751593
- DOI: 10.1159/000350512
Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection?
Abstract
Purpose: We evaluated the risk factors for residual tumor detection after transurethral resection of bladder tumors (TURBT) in patients with newly diagnosed high-grade T1 transitional cell carcinoma of the bladder.
Patients and methods: Overall 132 patients underwent TURBT for primary bladder tumors and were diagnosed as high-grade T1 bladder cancer. Patients with incomplete resections were excluded from the study. Clinical and pathologic characteristics of the patients were compared and multivariate analysis was performed to determine independent prognostic factors.
Results: Residual tumor was demonstrated in 57 (43.1%) of the patients. The residual tumor rate was significantly lower in patients with solitary tumors, tumors <3 cm in diameter, muscle presence in the initial TURBT pathologic sample and treated by an expert surgeon. In patients with solitary bladder tumors, tumors at the dome and posterior wall of the bladder exhibited higher rates of residual tumor (p < 0.0001). The time elapsed between first and second TURBT was significantly shorter in patients without residual tumor compared to patients with residual tumor at second TURBT (32.6 ± 9.1 vs. 39.3 ± 10.9 days, respectively, p = 0.001). Multivariate analysis demonstrated that time elapsed between first and second TURBT is the most important parameter for residual tumor detection.
Conclusion: Our study revealed that multiple tumors, tumors >3 cm in size, absence of detrusor muscle in the initial TURBT specimen, TURBT performed by trainees and finally, as a new finding, prolonged interval between first and second TURBT are independent predictors for residual tumor detection in patients with high-grade T1 tumors.
© 2013 S. Karger AG, Basel.
Similar articles
-
Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.BJU Int. 2013 Jul;112(1):54-9. doi: 10.1111/j.1464-410X.2012.11391.x. Epub 2012 Nov 13. BJU Int. 2013. PMID: 23146082
-
Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.BJU Int. 2012 Jun;109(11):1666-73. doi: 10.1111/j.1464-410X.2011.10571.x. Epub 2011 Nov 1. BJU Int. 2012. PMID: 22044434
-
Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.Urology. 2004 May;63(5):873-7; discussion 877. doi: 10.1016/j.urology.2003.12.035. Urology. 2004. PMID: 15134968
-
Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.J Urol. 2004 Jan;171(1):149-52. doi: 10.1097/01.ju.0000099825.98542.a8. J Urol. 2004. PMID: 14665864 Review.
-
A second-look TUR in T1 transitional cell carcinoma: why?Eur Urol. 2004 May;45(5):539-46; discussion 546. doi: 10.1016/j.eururo.2003.12.016. Eur Urol. 2004. PMID: 15082193 Review.
Cited by
-
Identification of potential prognostic factors for absence of residual disease in the second resection of T1 bladder cancer.Cent European J Urol. 2019;72(3):252-257. doi: 10.5173/ceju.2019.1908. Epub 2019 Sep 16. Cent European J Urol. 2019. PMID: 31720026 Free PMC article.
-
Recent Advances in Artificial Intelligence for Precision Diagnosis and Treatment of Bladder Cancer: A Review.Ann Surg Oncol. 2025 Aug;32(8):6173-6184. doi: 10.1245/s10434-025-17228-6. Epub 2025 Apr 12. Ann Surg Oncol. 2025. PMID: 40221553 Review.
-
Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.World J Surg Oncol. 2018 Jan 15;16(1):6. doi: 10.1186/s12957-018-1310-0. World J Surg Oncol. 2018. PMID: 29334958 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical